Clinical Trials Logo

PSA Progression clinical trials

View clinical trials related to PSA Progression.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03709550 Withdrawn - Clinical trials for Castration-Resistant Prostate Carcinoma

Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Start date: April 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of decitabine and how well it works when given together with enzalutamide in treating patients with castration resistant prostate cancer that has spread to other places in the body. Androgen can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, may lessen the amount of androgen made by the body. Decitabine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving decitabine and enzalutamide may work better in treating participants with castration resistant prostate cancer.